238 related articles for article (PubMed ID: 34488845)
1. Efficacy and safety of intramuscular administration of allogeneic adipose tissue derived and expanded mesenchymal stromal cells in diabetic patients with critical limb ischemia with no possibility of revascularization: study protocol for a randomized controlled double-blind phase II clinical trial (The NOMA Trial).
Soria-Juan B; Garcia-Arranz M; Llanos Jiménez L; Aparicio C; Gonzalez A; Mahillo Fernandez I; Riera Del Moral L; Grochowicz L; Andreu EJ; Marin P; Castellanos G; Moraleda JM; García-Hernández AM; Lozano FS; Sanchez-Guijo F; Villarón EM; Parra ML; Yañez RM; de la Cuesta Diaz A; Tejedo JR; Bedoya FJ; Martin F; Miralles M; Del Rio Sola L; Fernández-Santos ME; Ligero JM; Morant F; Hernández-Blasco L; Andreu E; Hmadcha A; Garcia-Olmo D; Soria B
Trials; 2021 Sep; 22(1):595. PubMed ID: 34488845
[TBL] [Abstract][Full Text] [Related]
2. Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial.
Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; McAuley DF; O'Kane C
Trials; 2022 May; 23(1):401. PubMed ID: 35562778
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic adipose tissue-derived mesenchymal stem cells in ischaemic stroke (AMASCIS-02): a phase IIb, multicentre, double-blind, placebo-controlled clinical trial protocol.
de Celis-Ruiz E; Fuentes B; Moniche F; Montaner J; Borobia AM; Gutiérrez-Fernández M; Díez-Tejedor E
BMJ Open; 2021 Aug; 11(8):e051790. PubMed ID: 34373315
[TBL] [Abstract][Full Text] [Related]
4. Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a Phase I/II randomised double-blind placebo-controlled trial.
Carlsson PO; Espes D; Sisay S; Davies LC; Smith CIE; Svahn MG
Diabetologia; 2023 Aug; 66(8):1431-1441. PubMed ID: 37221247
[TBL] [Abstract][Full Text] [Related]
5. A phase Ib/IIa, randomised, double-blind, multicentre trial to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for the treatment of patients with community-acquired bacterial pneumonia admitted to the intensive care unit.
Laterre PF; Sánchez-García M; van der Poll T; de la Rosa O; Cadogan KA; Lombardo E; François B
BMC Pulm Med; 2020 Nov; 20(1):309. PubMed ID: 33238991
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the SAIL trial for intramuscular injection of allogeneic mesenchymal stromal cells in no-option critical limb ischemia.
Wijnand JGJ; Teraa M; Gremmels H; van Rhijn-Brouwer FCC; de Borst GJ; Verhaar MC;
J Vasc Surg; 2018 Feb; 67(2):656-661. PubMed ID: 29242062
[TBL] [Abstract][Full Text] [Related]
7. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.
Uccelli A; Laroni A; Brundin L; Clanet M; Fernandez O; Nabavi SM; Muraro PA; Oliveri RS; Radue EW; Sellner J; Soelberg Sorensen P; Sormani MP; Wuerfel JT; Battaglia MA; Freedman MS;
Trials; 2019 May; 20(1):263. PubMed ID: 31072380
[TBL] [Abstract][Full Text] [Related]
8. Safety and clinical efficacy of the secretome of stressed peripheral blood mononuclear cells in patients with diabetic foot ulcer-study protocol of the randomized, placebo-controlled, double-blind, multicenter, international phase II clinical trial MARSYAS II.
Gugerell A; Gouya-Lechner G; Hofbauer H; Laggner M; Trautinger F; Almer G; Peterbauer-Scherb A; Seibold M; Hoetzenecker W; Dreschl C; Mildner M; Ankersmit HJ
Trials; 2021 Jan; 22(1):10. PubMed ID: 33407796
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II.
Fathi-Kazerooni M; Fattah-Ghazi S; Darzi M; Makarem J; Nasiri R; Salahshour F; Dehghan-Manshadi SA; Kazemnejad S
Stem Cell Res Ther; 2022 Mar; 13(1):96. PubMed ID: 35255966
[TBL] [Abstract][Full Text] [Related]
10. Reparative therapy for acute ischemic stroke with allogeneic mesenchymal stem cells from adipose tissue: a safety assessment: a phase II randomized, double-blind, placebo-controlled, single-center, pilot clinical trial.
Díez-Tejedor E; Gutiérrez-Fernández M; Martínez-Sánchez P; Rodríguez-Frutos B; Ruiz-Ares G; Lara ML; Gimeno BF
J Stroke Cerebrovasc Dis; 2014; 23(10):2694-2700. PubMed ID: 25304723
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of mesenchymal stem/stromal cell for radiation-induced hyposalivation and xerostomia in previous head and neck cancer patients (MESRIX-III): a study protocol for a single-centre, double-blinded, randomised, placebo-controlled, phase II study.
Jakobsen KK; Carlander AF; Grønhøj C; Todsen T; Melchiors J; Paaske N; Madsen AKØ; Kastrup J; Ekblond A; Haack-Sørensen M; Farhadi M; Maare C; Friborg J; Lynggard CD; von Buchwald C
Trials; 2023 Sep; 24(1):567. PubMed ID: 37658468
[TBL] [Abstract][Full Text] [Related]
12. PLX-PAD Cell Treatment of Critical Limb Ischaemia: Rationale and Design of the PACE Trial.
Norgren L; Weiss N; Nikol S; Hinchliffe RJ; Lantis JC; Patel MR; Reinecke H; Ofir R; Rosen Y; Peres D; Aberman Z
Eur J Vasc Endovasc Surg; 2019 Apr; 57(4):538-545. PubMed ID: 30686676
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial.
Nam JY; Lee TY; Kim K; Chun S; Kim MS; Shin JH; Sung JJ; Kim BJ; Kim BJ; Oh KW; Kim KS; Kim SH
Trials; 2022 May; 23(1):415. PubMed ID: 35585556
[TBL] [Abstract][Full Text] [Related]
14. A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia.
Gupta PK; Chullikana A; Parakh R; Desai S; Das A; Gottipamula S; Krishnamurthy S; Anthony N; Pherwani A; Majumdar AS
J Transl Med; 2013 Jun; 11():143. PubMed ID: 23758736
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of high-dose intramuscular vitamin D
Chen T; Xing X; Huang L; Tu M; Lai X; Wen S; Cai J; Lin S; Zheng Y; Lin Y; Xu L; Qiu Y; Qiu L; Xu Y; Wu P
Front Endocrinol (Lausanne); 2023; 14():1202917. PubMed ID: 37484958
[TBL] [Abstract][Full Text] [Related]
16. A novel therapeutic management for diabetes patients with chronic limb-threatening ischemia: comparison of autologous bone marrow mononuclear cells versus allogenic Wharton jelly-derived mesenchymal stem cells.
Arango-Rodríguez ML; Mateus LC; Sossa CL; Becerra-Bayona SM; Solarte-David VA; Ochoa Vera ME; Viviescas LTG; Berrio AMV; Serrano SE; Vargas O; Isla AC; Benitez A; Rangel G
Stem Cell Res Ther; 2023 Aug; 14(1):221. PubMed ID: 37626416
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stem cells in the treatment of Cesarean section skin scars: study protocol for a randomized, controlled trial.
Fan D; Xia Q; Wu S; Ye S; Liu L; Wang W; Guo X; Liu Z
Trials; 2018 Mar; 19(1):155. PubMed ID: 29499740
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic human umbilical cord-derived mesenchymal stem cells for severe bronchopulmonary dysplasia in children: study protocol for a randomized controlled trial (MSC-BPD trial).
Wu X; Xia Y; Zhou O; Song Y; Zhang X; Tian D; Li Q; Shu C; Liu E; Yuan X; He L; Liu C; Li J; Liang X; Yang K; Fu Z; Zou L; Bao L; Dai J
Trials; 2020 Jan; 21(1):125. PubMed ID: 32005282
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells (hUC-MSC PLEB001) for the treatment of grade II-IV steroid-refractory acute graft-versus-host disease: a study protocol for a multicenter, randomized, double-blind, placebo-controlled, phase II trial.
Yang D; Hou X; Qian K; Li Y; Hu L; Li L; Han M; Yao C; Liu D
Trials; 2023 May; 24(1):306. PubMed ID: 37138332
[TBL] [Abstract][Full Text] [Related]
20. A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC).
Ramsey ML; Nuttall J; Hart PA;
Trials; 2019 Aug; 20(1):501. PubMed ID: 31412955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
